CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China

Summary

The Chinese pharmaceutical market is the second largest in the world in terms of value. The increasing elderly population, expanding public insurance and regulatory reforms aimed at innovation and minimizing approval timelines are some of the factors driving the Chinese pharmaceutical market.

China Food and Drug Administration (CFDA) has released several policies to reform the healthcare market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.

The pharmaceutical industry - comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines - was valued at $168.6 billion in 2010 and grew to $424.6 billion in 2016. It is forecast to be $132.9 billion in 2018 and reach $209 billion by 2022.

The Chinese medical device market was valued at $36 billion in 2015, which increased to $40.1 billion in 2017. In order to further boost up the healthcare market, in September 2018, the Chinese government signed about $648 million worth of healthcare and life sciences deals with the UK government. The Chinese government also abolished the 15-year old government led drug pricing system and introduced a reform regarding drug pricing. This reform partially removed government control on drug prices, permitting more control of the market instead.

The latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China, is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China
  • Porter’s five forces analysis for pharmaceutical and medical devices market of China
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Chinese healthcare market.
Reasons to buy

This report will enhance your decision-making capability by allowing you to -
  • Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market.


Executive Summary
Overview of Pharmaceutical Market
Overview of Medical Device Market
Deals Analysis
Porter’s Five Forces Model
Market Access
Country Healthcare Landscape
Opportunities and Challenges
Appendix
List of Tables
Table 1: Biosimilars in Development by Chinese Companies, China, 2016
Table 2: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016
Table 3: Ophthalmic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 4: Orthopedic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 5: Diagnostic Imaging Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 6: Nephrology and Urology Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 7: Cardiovascular Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 8: Drug Classification System, China, 2017
Table 9: Medical Device Classification, China, 2016
Table 10: Trademark Process Timeline, China, 2017
Table 11: Documents for Advertising Application, China, 2017
Table 12: Label/Insert Sheet Information, China, 2017
Table 13: Key Improvement Indicators, Healthy China 2030
Table 14: Trade Fairs, China, 2018-2019
List of Figures
Figure 1: Pharmaceutical Market, China, Revenue ($bn), 2010-2017
Figure 2: Medical Device Market, China, Revenue ($bn), 2015-2020
Figure 3: Country Profile, China, 2017
Figure 4: Pharmaceutical Market, China, Revenue ($bn), 2010-2017
Figure 5: Pharmaceutical Market, China, Revenue Forecast ($bn), 2018-2022
Figure 6: Pharmaceutical Exports ($bn), China, 2010-2017
Figure 7: Top Export Partners, China, 2017
Figure 8: Pharmaceutical Imports ($bn), China, 2010-2017
Figure 9: Top Import Partners, China, 2017
Figure 10: USTR Findings, 2018
Figure 11: US-China Trade War Timeline, 2018
Figure 12: Pharmaceutical Drug Sales Channel, China, 2016
Figure 13: Supply Chain Prior to 2017
Figure 14: Two Invoice System
Figure 15: Policies for Biosimilar Promotion, China, 2018
Figure 16: Major Biosimilar Sales ($m), China, 2016
Figure 17: Traditional Chinese Medicine Production (10,000 tons), China, 2010-2016
Figure 18: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016
Figure 19: Pharmaceutical Market, Major Players, 2017
Figure 20: Medical Device Market, China, Revenue ($bn), 2015-2020
Figure 21: Medical Device Market, China, Revenue Forecast ($bn), 2021-2025
Figure 22: Medical Device Market, China, Revenue by Segment ($bn), 2017
Figure 23: Ophthalmic Devices Market, China, Revenue ($m), 2015-2022
Figure 24: Ophthalmic Devices Market, China, Market Share of Major Players (%), 2015
Figure 25: Orthopedic Devices Market, China, Revenue ($m), 2015-2020
Figure 26: Orthopedic Devices Market, China, Market Share of Major Companies (%), 2017
Figure 27: Diagnostic Imaging Devices Market, China, Revenue ($bn), 2015-2020
Figure 28: Diagnostic Imaging Devices Market, China, Market Share of Major Players (%), 2015
Figure 29: Nephrology and Urology Devices Market, China, Revenue ($m), 2015-2022
Figure 30: Nephrology and Urology Devices Market, China, Market Share of Major Players (%), 2016
Figure 31: Cardiovascular Devices Market, China, Revenue ($bn), 2015-2022
Figure 32: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2017
Figure 33: Diagnostic Market, China, Revenue ($bn), 2015-2020
Figure 34: Diagnostic Market, China, Revenue ($bn), 2021-2025
Figure 35: Medical Device Market, China, Revenue ($bn) of Major Companies, 2017
Figure 36: Deal Value and Deal Count, Pharmaceutical Market, China, 2017-2018
Figure 37: Deal Value and Deal Count Quarterly, Pharmaceutical Market, China, 2017-2018
Figure 38: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2017-2018
Figure 39: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, China, 2017-2018
Figure 40: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2017-2018
Figure 41: M&A Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
Figure 42: Venture Financing Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
Figure 43: Private Equity Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count)
Figure 44: Medical Device Market Deals (by deal value, $bn), China, 2017-2018
Figure 45: Medical Device Market Deals (by deal count), China, 2017-2018
Figure 46: Medical Device Market Deals Share (by deal count), China, 2017-2018
Figure 47:Medical Device Market Deals Share (by deal value), China, 2017-2018
Figure 48: Medical Device, China, Top Therapy Area by Deal Value, 2017-2018
Figure 49: Medical Devices, China, M&A Deals by Therapy Area, 2017-2018
Figure 50: Medical Devices, China, Venture Financing Deals by Therapy Area, 2017-2018
Figure 51: Medical Devices, China, Top Therapy Area by Deal Number, 2017-2018
Figure 52: Medical Devices, China, Private Equity Deals by Therapy Area, 2017-2018
Figure 53: Healthcare System, China, 2017
Figure 54: National Reimbursement Drug List Process, China, 2017
Figure 55: National Reimbursement Drug List Classification, China, 2017
Figure 56: Public Insurance Schemes, China, 2017
Figure 57: Out-of-Pocket Expenditure (% of total expenditure on health), China, 2010-2017
Figure 58: Annual Rate of Change (%), Health Care Price Index, China, 2010-2016
Figure 59: Pricing Policies, China, 2017
Figure 60: Drug Movement from Market Authorization to Patient Use, China, 2016
Figure 61: Ministry of Food and Drug Safety, Organization Chart, 2017
Figure 62: Timeline of CFDA Reforms, China, 2015-2018
Figure 63: Center for Drug Evaluation Organization Chart, China, 2017
Figure 64: Drug Approval Process, China, 2017
Figure 65: Generic Drug Approval Process, China, 2017
Figure 66: Medical Device Approval Process, China, 2017
Figure 67: Patent Approval Process, China, 2016
Figure 68: Proposed Patent Linkage System, China, 2017
Figure 69: Trademark Process, China, 2017
Figure 70: Advertising Application Approval Process, China, 2017
Figure 71: Key Announcements and Updates, Healthy China 2020, 2009-2016
Figure 72: Healthy China 2030, Strategic Goals
Figure 73: Hospitals (Number), China, 2010-2017
Figure 74: Hospitals by Type (Number), China, 2010-2017
Figure 75: Diagnostic Equipment (installed base), China, 2015-2012
Figure 76: Hospital Beds (per 1,000 population), China, 2010-2017
Figure 77: Medical Institution Beds (Urban)(per 1,000 population), China, 2010-2017
Figure 78: Medical Institution Beds (Rural)(per 1,000 population), China, 2010-2017
Figure 79: Life Expectancy (in years), China, 2010-2017
Figure 80: Immunization Rate (%), China, 2010-2017
Figure 81: PM2.5 (μg per m3), China, 2010-2017
Figure 82: CO2 Emissions (metric tons per capita), China, 2010-2017
Figure 83: Physicians (per 1,000 population), China, 2010-2017
Figure 84: Nurses (per 1,000 population), China, 2010-2017
Figure 85: Dentists, (per 1,000 population), China, 2010-2017
Figure 86: Pharmacists, (per 1,000 population), China, 2010-2017
Figure 87: Major Causes of Mortality (Death rate (%)), China, 2016
Figure 88: Major Causes of Male Mortality (Death rate (%)), China, 2016
Figure 89: Major Causes of Female Mortality (Death rate (%)), China, 2016
Figure 90: Disability-Adjusted Life Years by Major Disease (‘000), China, 2015
Figure 91: Healthcare Expenditure as Percentage of GDP (%), China, 2010-2017
Figure 92: Public-Private Share (%), China, 2010-2017
Figure 93: Opportunities & Challenges, China

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook